查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1736766

2026 年至 2032 年早產和胎膜早破檢測市場（按檢測類型、最終用戶和地區分類）

Preterm Birth and PROM Testing Market by Test Type (Preterm Birth Tests, PROM Tests), End-User (Hospitals, Diagnostics Laboratories), & Region for 2026-2032
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

早產和胎膜早破檢測市場評估—2026-2032

早產和胎膜早破 (PROM) 檢測市場專注於早產和胎膜早破的診斷和治療。早產率的上升和診斷技術的進步推動了這個市場的成長。隨著人們越來越意識到醫療保健的重要性，這個新興市場正在蓬勃發展。因此，市場規模預計在 2024 年將超過 23.9 億美元，並在 2032 年達到約 41.1 億美元的估值。

該市場正在開發用於早期檢測和管理的新型檢測方法。非侵入性操作和照護現場診斷正在定義未來。隨著醫療保健專業人員努力改善患者預後並預防早產問題，對準確快速觀察的需求正在推動市場成長。對早產和胎膜早破（PROM）檢測的需求不斷成長，使得市場在2026-2032年間的複合年成長率達到7.76%。

早產和胎膜早破檢測市場定義/概述

早產是指懷孕37週前分娩，可能導致嬰兒健康併發症。胎膜早破（PROM）檢測：評估胎膜早破（PROM，即分娩開始前羊膜囊破裂）有助於評估風險並指導處理，避免母嬰出現問題。

早產和胎膜早破 (PROM) 檢測有助於識別高風險懷孕。早產檢測可確定早產的可能性，胎膜早破 (PROM) 可偵測可偵測胎膜破裂，有助於預防感染疾病並控制早產風險。兩者對於早期療育和改善嬰兒結局都至關重要。

早產和胎膜早破（PROMs）檢測的未來應用包括提高早期發現率、指導標靶治療以及個人化治療方案。未來可能取得進展的途徑包括：結合預測性生物標記、建立非侵入性診斷方法以及修訂臨床指南，以最大程度地降低早產及其相關併發症的發生率。

早產盛行率的不斷上升是否會推動早產和胎膜早破檢測市場的成長？

由於早產率的上升，早產和胎膜早破（PROM）檢測產業必將蓬勃發展。到2021年，美國的早產率將從2020年的10.1%上升至10.5%，屆時將有近十分之一的嬰兒早產。從2014年到2021年，早產率上升了12%，全球每年約有1500萬名嬰兒早產。

胎膜早破 (PROM) 導致 2-3% 的妊娠併發症，並在美國造成 30-40% 的早產，凸顯了合適的診斷方案的重要性。胎膜早破盛行率的不斷上升凸顯了對新的診斷工具和干涉措施的需求，推動了市場擴張，因為醫療保健提供者正努力有效管理和降低早產及其相關後果的發生率。

高昂的檢測費用是否會阻礙早產和胎膜早破檢測市場的發展？

高昂的檢測費用可能會在一定程度上限制早產和胎膜早破檢測市場的發展。檢測成本受先進技術和醫療設施的影響，可能成為一大障礙，尤其是在資源匱乏的國家。

例如，在美國，早產管理成本高昂，醫療保健系統每例早產花費6.5萬美元，每年高達262億美元。如此高昂的成本可能會阻礙一些醫療保健相關人員和患者接受高級檢測。然而，這可能會推動市場對更經濟、更具成本效益的檢測方法和創新的需求。降低成本和提高可及性的努力有助於應對這些挑戰，同時支持整個產業的成長。

目錄

第1章 全球早產和妊娠檢測市場簡介

  • 市場概覽
  • 研究範圍
  • 先決條件

第2章執行摘要

第3章：已驗證的市場研究調查方法

  • 資料探勘
  • 驗證
  • 第一手資料
  • 資料來源列表

第4章全球早產及胎膜早破檢測市場展望

  • 概述
  • 市場動態
    • 驅動程式
    • 限制因素
    • 機會
  • 波特五力模型
  • 價值鏈分析

5. 全球早產和胎膜早破檢測市場（按類型）

  • 概述
  • 早產篩檢
    • 骨盆腔檢查
    • 超音波
    • 子宮監測
    • 生物標記
  • PROM測試
    • 硝嗪試驗
    • 範甯檢查
    • 池化
    • 超音波
    • 胎兒纖連蛋白檢測
    • 生物標記檢測

6. 全球早產及胎膜早破檢測市場（依最終用戶）

  • 概述
  • 醫院
  • 診斷實驗室
  • 其他

7. 全球早產及胎膜早破檢測市場（按地區）

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 其他
    • 拉丁美洲
    • 中東和非洲

8. 全球早產和胎膜早破檢測市場的競爭格局

  • 概述
  • 各公司市場排名
  • 重點發展策略

第9章 公司簡介

  • Qiagen Sciences, LLC
  • Hologic, Inc.
  • CooperSurgical, Inc
  • Abbott Laboratories
  • Medix Biochemica
  • Sera prognostics
  • Clinical Innovations, LLC
  • Biosynex
  • NX Prenatal, Inc.
  • IQ Products

第10章 附錄

  • 相關調查
簡介目錄
Product Code: 40822

Preterm Birth and PROM Testing Market Valuation - 2026-2032

The preterm birth and PROM (Premature Rupture of Membranes) testing market focuses on the diagnosis and treatment of early births and membrane rupture. The growth is being driven by rising preterm birth rates and advances in diagnostic technologies. Emerging markets are growing as people become more aware of the importance of healthcare. This is likely to enable the market size to surpass USD 2.39 Billion in 2024 to reach a valuation of around USD 4.11 Billion by 2032.

Leading manufacturers in this market are developing novel tests for early detection and management. Non-invasive procedures and point-of-care diagnostics are defining the future. Demand for precise, quick findings drives market growth as healthcare professionals strive to improve patient outcomes and prevent preterm birth problems. The rising demand for Preterm Birth and Prom Testing is enabling the market grow at a CAGR of 7.76% from 2026 to 2032.

Preterm Birth and PROM Testing Market: Definition/ Overview

Preterm birth is defined as a delivery occurring before 37 weeks of pregnancy, which may result in health complications for the baby. PROM Testing Evaluation for Premature Rupture of Membranes (PROM), in which the amniotic sac ruptures before labor begins, assesses risks and guides management to avoid difficulties for both mother and baby.

Preterm birth and PROM (preterm rupture of membranes) testing aid in detecting high-risk pregnancies. Preterm birth testing determines the possibility of early labor, whereas PROM testing detects membrane rupture, which helps to prevent infections and manage preterm delivery risks. Both are critical for early intervention and better infant outcomes.

Future applications of preterm birth and PROM (Premature Rupture of Membranes) testing include increasing early detection, guiding targeted therapies and personalizing treatment approaches. To minimize preterm birth rates and related difficulties, advances will be made by combining predictive biomarkers, establishing non-invasive diagnostic procedures and revising clinical guidelines.

Will Increasing Prevalence of Preterm Births Boost the Preterm Birth and PROM Testing Market Growth?

The rising occurrence of premature births will drive the preterm birth and PROM testing industry. In 2021, the U.S. preterm birth rate increasing to 10.5%, up from 10.1% in 2020, with almost one in every ten babies born preterm. Between 2014 and 2021, the rate climbed by 12%, with roughly 15 million babies born preterm around the world each year.

PROM complicates 2-3% of pregnancies in the United States and is connected with 30-40% of premature births, emphasizing the importance of appropriate diagnostic solutions. This rising incidence highlights the need for new diagnostic tools and interventions, which are driving market expansion as healthcare practitioners strive to effectively manage and reduce the occurrence of preterm births and related consequences.

Will High Cost of Testing Hamper the Preterm Birth and PROM Testing Market?

The high cost of testing may limit the preterm birth and PROM testing market to some extent. Testing costs, which are influenced by advanced technologies and healthcare facilities, can be a considerable barrier, especially in low-resource nations.

In the United States, for example, handling premature births incurs significant costs, with each case costing $65,000 and adding to a $26.2 billion yearly burden on the healthcare system. This hefty expense may dissuade some healthcare practitioners and patients from seeking advanced testing. However, it may increase demand for more economical, cost-effective testing methods and innovations in the marketplace. Efforts to lower costs and enhance accessibility could help to offset these issues while also supporting overall industry growth.

Category-Wise Acumens

Will Increasing Effectiveness in Monitoring Fetal and Uterine Health Drive the Test Type Segment?

Increasing efficacy in monitoring fetal and uterine health will drive the test type sector. Advances in technologies such as ultrasound and biomarker tests improve diagnostic accuracy, enabling for more effective care of preterm deliveries and PROM complications. Enhanced ultrasound capabilities offer more detailed images and insights into fetal development and uterine problems, resulting in better early identification and intervention techniques.

Similarly, advances in biomarker testing enable more exact identification of risk factors and illnesses. As these technologies improve in effectiveness, they are likely to gain traction and drive market expansion. The capacity to better monitor and manage pregnancy issues will result in increasing demand for advanced testing solutions, propelling the test type sector forward.

Will Increasing Wide Range of Diagnostic Tests and Immediate Clinical Interventions Drive the End-User Segment?

The growing number of diagnostic tests and the capacity to deliver quick clinical treatments will propel the end-user segment. Hospitals are well-positioned to profit from advances in diagnostic technologies because of their comprehensive care infrastructure, which includes access to a variety of diagnostic tests and specialists.

Hospitals are the recommended site for these services because they can perform a wide range of diagnostics, such as ultrasounds and biomarker assessments, as well as respond rapidly to preterm birth and PROM complications. As diagnostic capabilities improve and clinical interventions become more advanced, hospitals will continue to increase their use of preterm birth and PROM testing. This trend will continue to boost the end-user segment, cementing hospitals' dominance in this market.

Country/Region-wise Acumens

Will Advanced Healthcare Infrastructure Drive the Market in North America?

Advanced healthcare infrastructure will fuel the market in North America, enabling the region hold major share. According to the US Department of Health and Human Services, by 2020, 96% of non-federal acute care hospitals will have implemented certified electronic health records (EHRs). Additionally, 76% of U.S. hospitals used telemedicine technologies, such as video consultations, to improve patient care and access to services.

This solid infrastructure enables the effective deployment and maintenance of modern diagnostic tests for preterm delivery and PROM. The combination of EHRs and telemedicine enhances data management, diagnostic accuracy and allows for rapid treatments. These technological developments not only improve clinical capabilities, but also promote adoption of testing solutions, resulting in market growth in North America.

Will Increasing Healthcare Investments Drive the Market in Asia Pacific Region?

The Asia Pacific region is expected to exhibit rapid growth in the preterm birth and premature rupture of membranes (PROM) testing market due to increase in healthcare investments. This growth is primarily owing to improvement in healthcare infrastructure which results in better-equipped hospitals and clinics with advanced medical technologies, enhancing the capacity for more sophisticated prenatal care and diagnostic services. Thus, access to advanced diagnostic tools improves the accuracy and timeliness of diagnoses, leading to better outcomes for mothers and infants.

Aso, providing better training and education for healthcare professionals results in improved prenatal care and reduced incidence of preterm births and PROM. In response to the need for improvement in prenatal care, there is high demand for research and development activities in diagnostic tests and treatments, such as new biomarkers or non-invasive tests.

Public health campaigns can raise awareness about the risks of preterm birth and the importance of prenatal care, leading to earlier detection and prevention strategies. Expanding healthcare coverage can make prenatal testing more accessible and affordable for a larger population, increasing the usage of PROM and preterm birth testing services.

The implementation of maternal health programs is projected to facilitate the integration of preterm birth and PROM testing into broader maternal and child health programs, leading to better preventive care and management strategies.

Furthermore, increasing healthcare investments in the Asia Pacific region are expected to significantly boost the market for preterm birth and PROM testing, improving healthcare outcomes for mothers and babies while reducing long-term healthcare costs.

Competitive Landscape

The preterm birth and PROM testing market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the preterm birth and prom testing market include:

Qiagen N.V.

Hologic, Inc.

Cooper Surgical, Inc.

Abbott

Medixbiochemica

Sera Prognostics

Clinical Innovations, LLC

Biosynex

NX Prenatal, Inc.

1Q Products

Latest Developments

In May 2022, Sera Prognostics and the Newborn Foundation launched the Every Mother, Every Baby project. The purpose is to educate physicians, policymakers and public health stakeholders on the importance of validated biomarker-based preterm risk assessment tests, such as Sera's PreTRM test, in improving neonatal health outcomes maternal health outcomes.

In November 2021, Sera Prognostics has partnered with PreemieWorld, GLO Preemies and the Alliance for Black NICU Families to empower and support families affected by preterm birth.

Preterm Birth and Prom Testing Market, By Category

  • Test Type:
  • Preterm Birth Tests
  • Pelvic Exam
  • Ultrasound
  • Uterine Monitoring
  • Biomarker
  • PROM Tests
  • Nitrazine Test
  • Ferning Test
  • Pooling
  • Ultrasound
  • Fetal Fibronectin Test
  • Biomarker Test
  • End-User:
  • Hospitals
  • Diagnostics Laboratories
  • Region:
  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL PRETERM BIRTH AND PROM TESTING MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL PRETERM BIRTH AND PROM TESTING MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL PRETERM BIRTH AND PROM TESTING MARKET, BY TYPE

  • 5.1 Overview
  • 5.2 Preterm Birth Tests
    • 5.2.1 Pelvic Exam
    • 5.2.2 Ultrasound
    • 5.2.3 Uterine Monitoring
    • 5.2.4 Biomarker
  • 5.3 PROM Tests
    • 5.3.1 Nitrazine Test
    • 5.3.2 Ferning Test
    • 5.3.3 Pooling
    • 5.3.4 Ultrasound
    • 5.3.5 Fetal Fibronectin Test
    • 5.3.6 Biomarker Test

6 GLOBAL PRETERM BIRTH AND PROM TESTING MARKET, BY END USER

  • 6.1 Overview
  • 6.2 Hospitals
  • 6.3 Diagnostic Laboratories
  • 6.4 Others

7 GLOBAL PRETERM BIRTH AND PROM TESTING MARKET, BY GEOGRAPHY

  • 7.1 Overview
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 U.K.
    • 7.3.3 France
    • 7.3.4 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Rest of Asia Pacific
  • 7.5 Rest of the World
    • 7.5.1 Latin America
    • 7.5.2 Middle East and Africa

8 GLOBAL PRETERM BIRTH AND PROM TESTING MARKET COMPETITIVE LANDSCAPE

  • 8.1 Overview
  • 8.2 Company Market Ranking
  • 8.3 Key Development Strategies

9 COMPANY PROFILES

  • 9.1 Qiagen Sciences, LLC
    • 9.1.1 Overview
    • 9.1.2 Financial Performance
    • 9.1.3 Product Outlook
    • 9.1.4 Key Developments
  • 9.2 Hologic, Inc.
    • 9.2.1 Overview
    • 9.2.2 Financial Performance
    • 9.2.3 Product Outlook
    • 9.2.4 Key Developments
  • 9.3 CooperSurgical, Inc
    • 9.3.1 Overview
    • 9.3.2 Financial Performance
    • 9.3.3 Product Outlook
    • 9.3.4 Key Developments
  • 9.4 Abbott Laboratories
    • 9.4.1 Overview
    • 9.4.2 Financial Performance
    • 9.4.3 Product Outlook
    • 9.4.4 Key Developments
  • 9.5 Medix Biochemica
    • 9.5.1 Overview
    • 9.5.2 Financial Performance
    • 9.5.3 Product Outlook
    • 9.5.4 Key Developments
  • 9.6 Sera prognostics
    • 9.6.1 Overview
    • 9.6.2 Financial Performance
    • 9.6.3 Product Outlook
    • 9.6.4 Key Development
  • 9.7 Clinical Innovations, LLC
    • 9.7.1 Overview
    • 9.7.2 Financial Performance
    • 9.7.3 Product Outlook
    • 9.7.4 Key Developments
  • 9.8 Biosynex
    • 9.8.1 Overview
    • 9.8.2 Financial Performance
    • 9.8.3 Product Outlook
    • 9.8.4 Key Developments
  • 9.9 NX Prenatal, Inc.
    • 9.9.1 Overview
    • 9.9.2 Financial Performance
    • 9.9.3 Product Outlook
    • 9.9.4 Key Development
  • 9.10 IQ Products
    • 9.10.1 Overview
    • 9.10.2 Financial Performance
    • 9.10.3 Product Outlook
    • 9.10.4 Key Development

10 Appendix

  • 10.1 Related Research